Dr. Jonathan Thomas, President and CEO of the California Institute for Regenerative Medicine (CIRM), shares his insights on funding vital stem cell research. He discusses the importance of diversity in clinical trials to make treatments accessible. JT reflects on CIRM's 20-year journey in advancing research and training future scientists. The conversation also dives into balancing support between basic and clinical research, along with CIRM's strategic shift post-Proposition 14 to navigate the evolving landscape of regenerative medicine.